Two years after FDA’s breast density notification rule, there is still no standard for follow-up So far, 38 million patients have received a dense breast notification. Now what?

Beyond BRCA: Using AI to uncover the hidden architecture of hereditary cancer risk

A Fox Chase Cancer Center team is combining a rare longitudinal family cohort, whole-genome sequencing, AI-guided analysis, and laboratory validation to investigate why people with similar inherited susceptibility can experience very different cancer outcomes.

October 16, 2026

Vol.52 No.38

By Fox Chase Cancer Center

Cancer Policy

FDA launches Rare Disease Framework Initiative for drug development

FDA announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics for rare diseases.

October 16, 2026

Vol.52 No.38

Cancer Policy

FDA seeks nominations for the Tobacco Products Scientific Advisory Committee, announces new members

FDA is requesting nominations by Dec. 14 for voting members to serve on the Tobacco Products Scientific Advisory Committee.

October 16, 2026

Vol.52 No.38

Clinical Roundup

ACS studies find widening rural-urban survival and mortality gaps for women with breast cancer

Life-saving advances in breast cancer care are failing to reach rural America equally. In two large studies led by the American Cancer Society, scientists found that survival and mortality disparities between rural and urban women diagnosed with breast cancer widened over time in the United States.

October 16, 2026

Vol.52 No.38

Drugs & Targets

FDA approves atezolizumab + chemotherapy for stage 3 colon cancer

FDA approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair.

October 16, 2026

Vol.52 No.38

Drugs & Targets

FDA expands Anktiva approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover both papillary and CIS disease

FDA expanded the approved indication for Anktiva (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin to include patients with BCG-unresponsive NMIBC with papillary-only tumors.

October 16, 2026

Vol.52 No.38

Two years after FDA’s breast density notification rule, there is still no standard for follow-up

So far, 38 million patients have received a dense breast notification. Now what?

YOU MAY BE INTERESTED IN

Beyond BRCA: Using AI to uncover the hidden architecture of hereditary cancer risk

FDA launches Rare Disease Framework Initiative for drug development

FDA seeks nominations for the Tobacco Products Scientific Advisory Committee, announces new members

ACS studies find widening rural-urban survival and mortality gaps for women with breast cancer

FDA approves atezolizumab + chemotherapy for stage 3 colon cancer

FDA expands Anktiva approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover both papillary and CIS disease

Renew today!

Subscriber content

Never miss an issue!

Login